Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia a and B with inhibitors
Expert Rev Hematol. 2023 Aug 21. doi: 10.1080/17474086.2023.2248385. Online ahead of print.ABSTRACTINTRODUCTION: Bypassing agents (BPAs) are used to treat acute bleeding episodes, manage bleeding during perioperative care, and prophylactically minimize bleed occurrence in persons with hemophilia A or B with inhibitors (PwHABI). However, the effectiveness of BPAs that have been prescribed for the last several decades can be variable, motivating the development of a new recombinant activated factor VII, eptacog beta.AREAS COVERED: This review covers key eptacog beta findings from phase 1b and phase 3 (PERSEPT) clinical trial...
Source: Expert Review of Hematology - August 21, 2023 Category: Hematology Authors: Steven W Pipe Amy L Dunn Guy Young Source Type: research
Role of daratumumab in the frontline management of multiple myeloma: a narrative review
Expert Rev Hematol. 2023 Aug 18:1-18. doi: 10.1080/17474086.2023.2246651. Online ahead of print.ABSTRACTINTRODUCTION: The prevalence of multiple myeloma (MM) has gradually increased over the last few decades in India due to growing population, better disease awareness, and improved diagnostic procedures. Despite such advances, MM remains an incurable and relapsing disease due to its heterogeneity and genomic instability. With the inclusion of monoclonal antibodies, especially daratumumab in the frontline regimen, the management landscape of MM has improved significantly resulting in better disease control and patient outco...
Source: Expert Review of Hematology - August 16, 2023 Category: Hematology Authors: Sanjeev Yadav Sadashivudu Gundeti Abhay Bhave Uttiya Deb Jitendra Dixit Kundan Mishra Source Type: research
Role of daratumumab in the frontline management of multiple myeloma: a narrative review
Expert Rev Hematol. 2023 Aug 10. doi: 10.1080/17474086.2023.2246651. Online ahead of print.ABSTRACTINTRODUCTION: The prevalence of multiple myeloma (MM) has gradually increased over the last few decades in India due to growing population, better disease awareness and improved diagnostic procedures. Despite such advances, MM remains an incurable and relapsing disease due to its heterogeneity and genomic instability. With the inclusion of monoclonal antibodies, especially daratumumab in the frontline regimen, the management landscape of MM has improved significantly resulting in better disease control and patient outcomes.AR...
Source: Expert Review of Hematology - August 16, 2023 Category: Hematology Authors: Sanjeev Yadav Sadashivudu Gundeti Abhay Bhave Uttiya Deb Jitendra Dixit Kundan Mishra Source Type: research
Patient-centered care in von Willebrand disease: are we there yet?
We describe the importance of coordinated multidisciplinary care, as well as the need for patient education and empowered self-advocacy.EXPERT OPINION: While tremendous work has been done to improve the diagnosis and management of VWD, timely and high-quality research is urgently needed to address care gaps. Systemic changes such as resource investment, dedicated research funding for novel treatment modalities, and effective knowledge translation strategies to address structural barriers are needed to facilitate effective patient-centered care for VWD.PMID:37581602 | DOI:10.1080/17474086.2023.2243386 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - August 15, 2023 Category: Hematology Authors: Grace H Tang Jecko Thachil Mackenzie Bowman Carine Bekdache Paula D James Michelle Sholzberg Source Type: research
